aTyr Pharma宣布：在下一项三期临床试验中，将5.0毫克/公斤Efzofitimod或安慰剂的给药频率提升至每三周一次

美股速递05-12

生物制药公司aTyr Pharma Inc. 已公布其下一阶段三期临床试验方案的调整细节。核心变动在于，试验药物Efzofitimod（剂量为5.0毫克/公斤）及其对照安慰剂的给药频率，将从原有方案增加至每三周进行一次。这一调整旨在进一步评估该药物在延长给药间隔下的疗效与安全性表现，为后续的临床开发与潜在上市申请收集关键数据。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1177763181?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-05-12 04:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1177763181","market":"us","top_or_hot":-1,"title":"aTyr Pharma宣布：在下一项三期临床试验中，将5.0毫克/公斤Efzofitimod或安慰剂的给药频率提升至每三周一次","media":"美股速递","content":"<p>生物制药公司aTyr Pharma Inc. 已公布其下一阶段三期临床试验方案的调整细节。核心变动在于，试验药物Efzofitimod（剂量为5.0毫克/公斤）及其对照安慰剂的给药频率，将从原有方案增加至每三周进行一次。这一调整旨在进一步评估该药物在延长给药间隔下的疗效与安全性表现，为后续的临床开发与潜在上市申请收集关键数据。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>aTyr Pharma宣布：在下一项三期临床试验中，将5.0毫克/公斤Efzofitimod或安慰剂的给药频率提升至每三周一次</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\naTyr Pharma宣布：在下一项三期临床试验中，将5.0毫克/公斤Efzofitimod或安慰剂的给药频率提升至每三周一次\n</h2>\n\n<h4 class=\"meta\">\n\n2026-05-12 04:04 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>生物制药公司aTyr Pharma Inc. 已公布其下一阶段三期临床试验方案的调整细节。核心变动在于，试验药物Efzofitimod（剂量为5.0毫克/公斤）及其对照安慰剂的给药频率，将从原有方案增加至每三周进行一次。这一调整旨在进一步评估该药物在延长给药间隔下的疗效与安全性表现，为后续的临床开发与潜在上市申请收集关键数据。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ATYR","symbol_name":"ATYR PHARMA INC","start_time":0,"source_url":"","article_id":"1177763181","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1177763181","pubTimestamp":1778529858,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"生物制药公司aTyr Pharma Inc. 已公布其下一阶段三期临床试验方案的调整细节。核心变动在于，试验药物Efzofitimod（剂量为5.0毫克/公斤）及其对照安慰剂的给药频率，将从原有方案增加至每三周进行一次。这一调整旨在进一步评估该药物在延长给药间隔下的疗效与安全性表现，为后续的临床开发与潜在上市申请收集关键数据。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"ATYR":"ATYR PHARMA INC","BK4139":"生物科技"},"translate_title":"aTyr Pharma announces that it will increase the frequency of 5.0 mg/kg Efzofitimod or placebo to once every three weeks in the next phase III clinical trial","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATYR":1},"content_text":"生物制药公司aTyr Pharma Inc. 已公布其下一阶段三期临床试验方案的调整细节。核心变动在于，试验药物Efzofitimod（剂量为5.0毫克/公斤）及其对照安慰剂的给药频率，将从原有方案增加至每三周进行一次。这一调整旨在进一步评估该药物在延长给药间隔下的疗效与安全性表现，为后续的临床开发与潜在上市申请收集关键数据。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1177763181","isCrawlerRequest":true}